Search Results - "Araki, Kazuhiro"

Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer by Araki, Kazuhiro, Miyoshi, Yasuo

“…Endocrine therapy is a crucial treatment for estrogen receptor-positive (ER+) breast cancer, with proven clinical benefits. However, adaptive mechanisms emerge…”
Get full text

Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel by Araki, Kazuhiro, Ito, Yoshinori, Fukada, Ippei, Kobayashi, Kokoro, Miyagawa, Yoshimasa, Imamura, Michiko, Kira, Ayako, Takatsuka, Yuichi, Egawa, Chiyomi, Suwa, Hirofumi, Ohno, Shinji, Miyoshi, Yasuo

“…Although peripheral blood-based parameters (PBBPs) are reported as prognostic indicators in patients with breast cancers, their utility has not been studied in…”
Get full text

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy by Kikawa, Yuichiro, Hagiwara, Yasuhiro, Fujisawa, Tomomi, Araki, Kazuhiro, Iwamoto, Takayuki, Sangai, Takafumi, Shien, Tadahiko, Takao, Shintaro, Nishimura, Reiki, Takahashi, Masato, Toyama, Tatsuya, Aihara, Tomohiko, Mukai, Hirofumi, Taira, Naruto

“…The HORSE-BC study previously demonstrated that second-line endocrine therapy (ET) for patients with acquired endocrine-resistant metastatic breast cancer…”
Get full text

Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy by Yuichiro Kikawa, Yasuhiro Hagiwara, Tomomi Fujisawa, Kazuhiro Araki, Takayuki Iwamoto, Takafumi Sangai, Tadahiko Shien, Shintaro Takao, Reiki Nishimura, Masato Takahashi, Tatsuya Toyama, Tomohiko Aihara, Hirofumi Mukai, Naruto Taira

“…BackgroundThe HORSE-BC study previously demonstrated that second-line endocrine therapy (ET) for patients with acquired endocrine-resistant metastatic breast…”
Get full text

Invasive pulmonary aspergillosis due to Aspergillus lentulus in an adult patient: A case report and literature review by Yagi, Kazuma, Ushikubo, Mari, Maeshima, Arafumi, Konishi, Misako, Fujimoto, Kazuyuki, Tsukamoto, Masako, Araki, Kazuhiro, Kamei, Katsuhiko, Oyamada, Yoshitaka, Oshima, Hisaji

“…Aspergillus fumigatus is the commonest cause of pulmonary aspergillosis; however, a recently developed molecular genetic technique identified A. lentulus as a…”
Get full text

Ribociclib for HR-Positive, Advanced Breast Cancer by Araki, Kazuhiro, Miyoshi, Yasuo, de Gramont, Armand, Herrera, Alain, de Gramont, Aimery, Hortobagyi, Gabriel N

“…To the Editor: In their interim analysis of the Mammary Oncology Assessment of LEE011’s (Ribociclib’s) Efficacy and Safety (MONALEESA-2) trial, Hortobagyi et…”
Get full text

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors by Minami, Hironobu, Kawada, Kenji, Ebi, Hiromichi, Kitagawa, Koichi, Kim, Yon‐il, Araki, Kazuhiro, Mukai, Hirofumi, Tahara, Makoto, Nakajima, Hikaru, Nakajima, Keiko

“…Sorafenib is a novel oral multikinase inhibitor that targets Raf serine/threonine and receptor tyrosine kinases, and inhibits tumor cell proliferation and…”
Get full text

Good Immunogenicity of Delayed Second Dose of BNT162b2 Vaccine in Individuals with Acute Allergic-like Reactions after the First Dose by Araki, Kazuhiro, Shimizu, Nobuaki, Iijima, Misa, Hosaka, Hisashi, Yanagita, Yasuhiro

“…We assessed SARS-CoV-2 anti-spike immunoglobulin G (anti-S-IgG) levels among healthcare workers (HCWs) after BNT162b2 vaccination. The anti-S-IgG titers of…”
Get full text

Anti-cyclic citrullinated peptide antibody in the cerebrospinal fluid in patients with rheumatoid arthritis who have central nervous system involvement by Higashida-Konishi, Misako, Izumi, Keisuke, Tsukamoto, Masako, Ohya, Hiroaki, Takasugi, Nozomi, Hama, Satoshi, Hayashi, Yutaro, Ushikubo, Mari, Akiya, Kumiko, Kazuhiro, Araki, Okano, Yutaka, Oshima, Hisaji

“…Central nervous system (CNS) involvement, including encephalopathy, encephalitis, leptomeningitis, and pachymeningitis, in rheumatoid arthritis (RA) is rather…”
Get full text

Switching cisplatin to carboplatin in chemotherapy for metastatic penile cancer in a patient intolerant to cisplatin by Sekine, Keita, Suyama, Takahito, Takei, Kazuki, Kato, Hiroto, Wakai, Ken, Okato, Atsushi, Hou, Kyokushin, Araki, Kazuhiro, Yamazaki, Kazuto, Naya, Yukio

“…Introduction Cisplatin is currently the key drug in the chemotherapy regimen for metastatic penile cancer. There are few reports of alternative medicines for…”
Get full text

Laparoscopic redo pyeloplasty with a buccal mucosal graft by Shimizu, Nobuhiko, Naya, Yukio, Sekine, Keita, Hou, Kyokushin, Okato, Atsushi, Suyama, Takahito, Araki, Kazuhiro, Masuda, Hiroshi, Kojima, Satoko

“…Introduction Redo pyeloplasty can be difficult due to scar tissue or fibrosis. Ureteral reconstruction with a buccal mucosal graft is performed safely and…”
Get full text

Outcomes of dutasteride discontinuation in patients with benign prostatic hypertrophy by Masuda, Hiroshi, Mikami, Kosuke, Otsuka, Kotaro, Hou, Kyokusin, Suyama, Takahito, Araki, Kazuhiro, Kojima, Satoko, Naya, Yukio

“…To the Editor, Benign prostatic hyperplasia (BPH) is a common cause of lower urinary tract symptoms (LUTS) in elderly males. The current guidelines recommend…”
Get full text

Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer by Araki, Kazuhiro, Miyoshi, Yasuo

Get full text

The choice of therapeutic agent in female overactive bladder patients in real-world practice by Masuda, Hiroshi, Mikami, Kosuke, Otsuka, Kotaro, Hou, Kyokusin, Suyama, Takahito, Araki, Kazuhiro, Kojima, Satoko, Naya, Yukio

“…The reasons why anticholinergic drugs or β3 adrenergic agonists are selected as treatments for overactive bladder (OAB) are unclear. The aim of this study was…”
Get full text

A Review Multigene Assays for Clinical Utility in Breast Cancer by Araki, Kazuhiro, Ito, Yoshinori

“…Multigene assays that simultaneously measure the expression of various breast cancer genes have been developed to guide the use of adjuvant chemotherapy in…”
Get more information

Identification of B.1.346 Lineage of SARS-CoV-2 in Japan: Genomic Evidence of Re-entry of Clade 20C by Abe, Kodai, Shimura, Takako, Takenouchi, Toshiki, Iwasaki, Yuka W., Ishizu, Hirotsugu, Uwamino, Yoshifumi, Uno, Shunsuke, Gotoh, Jun, Tachikawa, Natsuo, Takeuchi, Yuriko, Katayama, Junpei, Nozaki, Hiroyuki, Fujii, Susumu, Seki, Shikou, Nakamura, Morio, Uda, Kazuhiro, Misumi, Takahiko, Ishihara, Jun, Yamada, Kenichiro, Kanai, Toshio, Murai, Shinji, Araki, Kazuhiro, Ebihara, Tamotsu, Siomi, Haruhiko, Hasegawa, Naoki, Kitagawa, Yuko, Amagai, Masayuki, Suematsu, Makoto, Kosaki, Kenjiro

“…SARS-CoV-2 whole-genome sequencing of samples from COVID-19 patients is useful for informing infection control. Datasets of these genomes assembled from…”
Get full text

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) by Yamashita, Toshinari, Masuda, Norikazu, Saji, Shigehira, Araki, Kazuhiro, Ito, Yoshinori, Takano, Toshimi, Takahashi, Masato, Tsurutani, Junji, Koizumi, Kei, Kitada, Masahiro, Kojima, Yasuyuki, Sagara, Yasuaki, Tada, Hiroshi, Iwasa, Tsutomu, Kadoya, Takayuki, Iwatani, Tsuguo, Hasegawa, Hiroki, Morita, Satoshi, Ohno, Shinji

“…Trastuzumab (Tmab), pertuzumab (Pmab), and taxane has been a standard first-line treatment for recurrent or metastatic human epidermal growth factor…”
Get full text

The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs by Iwamoto, Takayuki, Fujisawa, Tomomi, Shien, Tadahiko, Araki, Kazuhiro, Sakamaki, Kentaro, Sangai, Takafumi, Kikawa, Yuichiro, Takao, Shintaro, Nishimura, Reiki, Takahashi, Masato, Aihara, Tomohiko, Mukai, Hirofumi, Taira, Naruto

“…Purpose Second-line endocrine therapy (ET) for estrogen receptor (ER)-positive and human epidermal growth factor 2 (HER2)-negative metastatic breast cancer…”
Get full text

Correction to: Anti-cyclic citrullinated peptide antibody in the cerebrospinal fluid in patients with rheumatoid arthritis who have central nervous system involvement by Higashida-Konishi, Misako, Izumi, Keisuke, Tsukamoto, Masako, Ohya, Hiroaki, Takasugi, Nozomi, Hama, Satoshi, Hayashi, Yutaro, Ushikubo, Mari, Akiya, Kumiko, Kazuhiro, Araki, Okano, Yutaka, Oshima, Hisaji

“…The authors regret that the original published version of the above article contained errors. The authors requested that these be noted…”
Get full text

High Serum Alkaline Phosphatase Flare after First-Line Androgen Deprivation Therapy Predicts Poor Prognosis in Metastatic Prostate Cancer Patients Treated with Second-Generation Androgen Receptor Targeted Therapy by Kojima, Satoko, Masuda, Hiroshi, Suyama, Takahito, Hou, Kyokushin, Mikami, Kousuke, Araki, Kazuhiro, Naya, Yukio

“…Objectives. To determine whether an alkaline phosphatase (ALP) flare after androgen deprivation therapy (ADT) is associated with the treatment response in…”
Get full text